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Depletion of Glutathione and enhanced lipid peroxidation in the CSF of Acute 
Psychotics following haloperidol administration. 
Abstract 
Haloperidol administration for 2 weeks results in significant reduction in the concentration of GSH in the 
CSF. Concomitantly, the levels of lipid peroxidation products increased as evidenced by increased 
malondialdehyde levels. The malondialdehyde levels in the CSF prior to haloparidol administration were 
not significantly higher than that seen in CSF from normal controls (data not shown) suggesting that 
increased oxidative stress did not exist in these patients prior to haloperidol administration. All the 
patients included in the present study were drug naive and hence the changes observed in the glutathione 
and malon6ialdehyde levels in the CSF were indeed mediated by haloperidol administration. The only 
other medication that was administered namely, anticholinergic drug, trihexyphenidyl is not known to 
cause any oxidative stress. The present study thus demonsuates that haloperidol administration results 
in significant oxidative stress. The generation of the oxidative stress is probably due to the increased 
turnover of dopemine caused by typical neuroleptics. Increased dopamine turnover is also observed in 
Parkinson's disease and the combination therapy consisting of antioxidant vitamin E and monoamine 
oxidase inhibitor, deprenyl has been shown to offer limited protection against the progression of the 
disease (Parkinson Disease Study Group 1989). In the present study, all the 15 patients exhibited 
extrapyramidal symptoms although the time of onset, the duration and the severity of the side effects 
differed between patients. On the presumption that the oxidative stress generated by haloperidel may 
cause extrapyramidal symptoms, the present study in humans taken together with the evidence provided 
in our earlier studies on rats (Shivakumar and Ravindranath 1992,1993) may justify experimental 
coadministration of antioxidanls (e.g., vitamin E) with typical neuroleptics like haloperidol to prevent the 
acute side effects. 
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Introduction 
The usage of typical ncumleptic drugs has been limited by the side 
effects and toxicity produced by them. The major side effects are 
the range of extrapyramidal symptoms including neumleptic ma- 
lignant syndrome and tardive dyskinesia. The pharmacological 
action of neumleptics is associated with their antagonist action on 
dopamine receptor. The blockade of dopamine receptors by neuro- 
leptics leads to increased turnover of  dopamine as demonstrated by 
increased levels of the dopamine metabolite, homovanillic acid in 
the cerebrospinal fluid (Scatton et al 1977). Dopamine is metabo- 
lized by monoamine oxidase (MAO) as given below: 
Dopamine + Oxygen + Water MAO:~. Hydrogen Peroxide + 
Ammonia + 3,4 Dihydroxy phenylacetaldehyde 
Hydrogen peroxide is a potent oxidant and can react with iron 
(Fe z*) or copper (Cu 2÷) to form the highly toxic hydroxyl radical. 
Reactive oxygen species such as hydrogen peroxide and hydroxyl 
r~:rl;,-.21 ~ , t  ~-.rt,~neiu,aha sui th  r,all:, |car r.,-tnetih:~nte :,,~mng t,,,,v;_ 
dative damage to proteins, lipids, and deoxyribose nucleic acid 
(DNA). The hydroxyl radical can set up a chain reaction leading to 
peroxidation of lipids thus damaging the integrity of cell mem- 
branes (Halliwel11992). 
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Acute (Shivakumar and Ravindranath 1992) and chronic (Shi- 
vakumar and Ravindranath 1993) ~ n i s t r a t i o n  of I,.aloperidol (a 
neuroleptic belonging to the class of butyropbenones) to rats re- 
sulted in the generation of significant oxidative stress in brain 
regions as evidenced by the loss of the nonprotein thiol antioxidant 
glutathione (GSH) and increase in the lipid peroxidation product, 
malondialdehyde. The depleted GSH is essentially recovered as 
pmtein-GSH mixed disulfide and the oxidized GSH (GSSG) 
levels were not elevated substantially. Extensive modification of 
the protein thiols was also detected, which could be attributed to 
the formation of protein glutathione mixed disulfides and protein 
mixed disulfides. Because GSH is responsible for the maintenance 
of protein thiol homeostasis in the ceil, the depletion of GSH levels 
also contributes to the disturbance in the protein thiol homeostasis. 
The generation of oxidative stress in humans by halopeddol 
administration is yet to be demonstrated although it has been 
hypothesized that the toxic side effects seen in man may be due to 
the generation of oxidative stress caused by increased dopamine 
turnover (Cadet et al 1986). In an earlier study, Pall et al observed 
that phenothiazines increased lipid peroxidation in the cerebro- 
spinal fluid (CSF) of a diagnostically heterogeneous group of 
patients (Pall et al 1989). Coadrninistration of vitamin E with 
haloperidol resulted in some beneficial effect in patients with 
tardive dyskinesia (Lohr et al I988). Two recent studies have 
reported little or no beneficial effect of antioxidant therapy in 
tardive dyskinesia (Shriqui et al, 1991 and Egan et al 1991), how- 
ever, to our knowledge, no information is available on the antioxi- 
dant status following administration of haloperidol. 
In the present study, the concentIation of GSH and the lipid 
peroxidation product., malondialdehyde were estimated in the CSF 
of & ag-naive acute psychotic patients before and after 2 weeks of 
haloperidol administration. 
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Figure I. The concentration of (A) glutathione and (B) malondialdehyde in the CSF of patients 
before and after haloperidol administration. Glutathione levels were measured in the CSF before 
(A) after (&) haloperidol administration. The levels of malondialdehyde were also determined 
before (O) and after (O) haloperidol treatment. 
Methods 
Patients 
lnpatients of both the sexes aged 17-40 years who met the diag- 
nostic criteria for acute and transient psychosis (F23) of the !CD- 
10 (World Health Organization 1990) formed the sample of the 
study. Informed consent was obtained from the patients for (!)  the 
inpatient stay of at least 2 weeks, (2) treatment with haloperidol, 
and (3) two lumbar punctures before and after h~operidol admin- 
istration for 2 weeks. No patient had clinical evidence of nutri- 
tional deficiency, ~urological illness, or associated infections. 
None of the patients had a history of alcohol or substance abuse 
and none had received neuroleptics or electroconvulsive therapy 
before. Routine investigations that included blood counts, fasting 
blood sugar, serum cholesterol, liver and renal function tests were 
normal in all the patients. Similarly, patients had normal blood 
vidal test and serological tests for syphilis. 
Patients received oral haloperidol (10 rag/day) for a period of 2 
weeks. The anticholinergic drug, trihexyphenidyl (2-4 rag/day) 
was administered to all the patients only when the patients mani- 
fested extrapyramidal symptoms impairing their daily activities. 
The anticholinergic drug was introduced at varying time points 
during the 2-week period of haloperidol therapy. No other medica- 
tion was used during the tint 2 weeks of haloperidol treatment. 
Assessment 
The psychopathology of the patients was rated using the Brief 
Psychiatric Rating Scale (BPRS, Overall and Gotham 1962) be- 
fore treatment and after ! and 2 weeks of  treatment. Before halo- 
peridol administration was started, and after 2 weeks of haloperi- 
dol treatment, CSF was collected by lumbar puncture between the 
b - L ,  disc spaces. CSF samples were aliquoted and two aliquots 
were frozen immediately and stored at -20°C. GSH levels in the 
CSF were estimated using the enzymatic recycfing method (Tietz 
1969) and malondialdehyde was estimated as thiobarbituric acid 
reactive products (Ohkawa et al 1979). All biochemical analyses 
were carried out blind to patient status. One aliquot of  the CSF was 
used for the estimation of protein, glucose, and cell count, which 
was carried out on the same day as the lumbar puncture. Only 
patients with normal CSF (as evidenced by normal cell count, 
protein, and glucose levels) were included in the study and contin- 
ued to receive haloperidol for 2 weeks. Thereafter, another lumbar 
puncture was performed and the CSF was collected and used as 
before. The patient group was comprised of 15 individuals (8 
women) with mean age (SD) of 26.7 (6.8) years. The mean (SD) 
duration of illness was 11.2 (7) days. Significant reductions in 
BPRS scores from a mean (SD) of 37.3 (4.2) to 22.4 (3.2) was 
observed at the end of the 2 weeks of treatment. 
Results 
The GSH levels in the CSF decreased significantly after 2 weeks of 
haloperidol administration. The average decrease in GSH levels 
was 76% as compared to pretreatment levels. The mean GSH 
levels in the CSF were 2.6 (0.7) and 0.6 (0.13) p.moles/100 ml 
before and after haloperidol administration, respectively. The de- 
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crease in GSH levels was noted in all the patients included in the 
study and it varied between 93% to 21% depletion. Concomitant 
with the GSH decrease, the CSF malondialdehyde levels (indica- 
tive of  lipid peroxidation products) i ~  after halolmidol 
administration. The average increase was 86% as compared :o 
prelreatmont levels. The mean (SEM) malondialdehyde levels 
were 20.0 (4.0) and 36.2 (5.5) nmoles of malondialdehyde/100 mi 
CSF before and after haloparidol administration. The increase in 
malondialdehyde ranged from 105% to 625% of the lnetreatm~nt 
levels, In 2 out of the 15 sets of samples analyzed, no increase was 
observed in malondialdehyde levels after haloperidol adtMnisua- 
don (Figure !). 
Discussion 
Haloperidol administration for 2 weeks results in significant re- 
duction in the concentralion of GSH in the CSF. Concomitantly, 
the levels of lipid peroxidation products increased as evidenced by 
increased malondialdehyde levels. The mdlondialdehyde levels in 
the CSF prior to haloparidol administration were not significantly 
higher than that seen in CSF from normal controls (data not 
shown) suggesting that increased oxidative stress did not exist in 
these patients prior to haloperidol administration. All the patients 
included in the presem study were drug n~ive and hence the 
changes observed in the glutathione and malon6ialdehyde levels 
in the CSF were indeed mediau~tl by haloperidol adminislration. 
The only other medication that was ~ namely, 
anticholinergic drug, uihexyphenidyl is not known to ~ a ~  
oxidative stress. 
The present study thus demonsuates that ~ ad~J#~s- 
uafion n~mlts in significant oxidative ~ .  The ~ of die 
oxidative mess is probably due to the increased turnover of dope- 
mine caused by typical ~ .  Increased depamiee tm~over 
is also observed in Parkimon's ~ a~d the combination ther- 
apy consisting of an|ioxidant vitamin E and monoamine oxidase 
inhibitor, depronyl has been shown to offer ~ 
against the progression of the disease (Patkinson ~ Study 
Group 1989). 
In the present study, all the 15 ~ exhibited extrai~ramidal 
symptoms although the time of oeset, the duration and the severity 
of the side effects differed be~*ween patients. On the presumption 
that the oxidative stress generated by haloperidel may cause extra- 
pyramidal symptoms, the present study in humans taken together 
with the evidence provided in our earlier studies on rats (Shivaku- 
mar and Ravindranath 1992,1993) may justify experimental coad- 
ministration of antioxidanls (e.g., vitamin E) with typical neuro- 
leptics like haloperidol to prevent the acute side effects. 
The authors thank Dr. B.R. Shivakumar and Dr. K. Sadashiv PaJ for help 
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